Parallel Advisors’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $22.6M | Buy |
103,875
+1,290
| +1% | +$286K | 0.41% | 45 |
|
|
2025
Q4 | $23.4M | Sell |
102,585
-2,628
| -2% | -$599K | 0.43% | 39 |
|
|
2025
Q3 | $24.4M | Buy |
105,213
+599
| +0.6% | +$122K | 0.45% | 37 |
|
|
2025
Q2 | $19.4M | Sell |
104,614
-2,428
| -2% | -$451K | 0.39% | 42 |
|
|
2025
Q1 | $22.4M | Sell |
107,042
-1,143
| -1% | -$222K | 0.51% | 30 |
|
|
2024
Q4 | $19.2M | Sell |
108,185
-620
| -0.6% | -$114K | 0.43% | 41 |
|
|
2024
Q3 | $21.5M | Sell |
108,805
-1,302
| -1% | -$243K | 0.51% | 28 |
|
|
2024
Q2 | $18.9M | Sell |
110,107
-1,340
| -1% | -$222K | 0.48% | 32 |
|
|
2024
Q1 | $20.3M | Buy |
111,447
+1,043
| +0.9% | +$180K | 0.55% | 25 |
|
|
2023
Q4 | $17.1M | Sell |
110,404
-1,755
| -2% | -$256K | 0.51% | 36 |
|
|
2023
Q3 | $16.7M | Buy |
112,159
+1,659
| +2% | +$244K | 0.56% | 34 |
|
|
2023
Q2 | $14.9M | Sell |
110,500
-1,315
| -1% | -$193K | 0.48% | 43 |
|
|
2023
Q1 | $17.8M | Buy |
111,815
+75,111
| +205% | +$11.5M | 0.6% | 30 |
|
|
2022
Q4 | $5.93M | Buy |
36,704
+3,307
| +10% | +$507K | 0.26% | 64 |
|
|
2022
Q3 | $4.48M | Buy |
33,397
+2,537
| +8% | +$364K | 0.21% | 79 |
|
|
2022
Q2 | $4.73M | Sell |
30,860
-420
| -1% | -$64.2K | 0.22% | 74 |
|
|
2022
Q1 | $5.12M | Sell |
31,280
-322
| -1% | -$46.8K | 0.2% | 80 |
|
|
2021
Q4 | $4.28M | Buy |
31,602
+3,263
| +12% | +$385K | 0.16% | 102 |
|
|
2021
Q3 | $3.06M | Buy |
28,339
+187
| +0.7% | +$21.4K | 0.12% | 123 |
|
|
2021
Q2 | $3.17M | Buy |
28,152
+3,137
| +13% | +$353K | 0.13% | 114 |
|
|
2021
Q1 | $2.71M | Buy |
25,015
+1,287
| +5% | +$138K | 0.13% | 118 |
|
|
2020
Q4 | $2.54M | Sell |
23,728
-1,549
| -6% | -$149K | 0.14% | 114 |
|
|
2020
Q3 | $2.21M | Buy |
25,277
+805
| +3% | +$75.8K | 0.14% | 125 |
|
|
2020
Q2 | $2.4M | Buy |
24,472
+1,827
| +8% | +$161K | 0.16% | 101 |
|
|
2020
Q1 | $1.73M | Buy |
22,645
+13
| +0.1% | +$1.11K | 0.14% | 112 |
|
|
2019
Q4 | $2M | Buy |
22,632
+97
| +0.4% | +$8.05K | 0.15% | 117 |
|
|
2019
Q3 | $1.71M | Sell |
22,535
-6,381
| -22% | -$437K | 0.15% | 119 |
|
|
2019
Q2 | $2.1M | Buy |
28,916
+3,167
| +12% | +$249K | 0.21% | 88 |
|
|
2019
Q1 | $2.08M | Sell |
25,749
-441
| -2% | -$36.1K | 0.23% | 84 |
|
|
2018
Q4 | $2.41M | Buy |
26,190
+736
| +3% | +$64.7K | 0.34% | 56 |
|
|
2018
Q3 | $2.41M | Buy |
25,454
+4,369
| +21% | +$414K | 0.3% | 62 |
|
|
2018
Q2 | $1.95M | Buy |
21,085
+4,623
| +28% | +$451K | 0.28% | 62 |
|
|
2018
Q1 | $1.56M | Buy |
16,462
+153
| +0.9% | +$16.8K | 0.24% | 78 |
|
|
2017
Q4 | $1.58M | Sell |
16,309
-376
| -2% | -$35.4K | 0.26% | 73 |
|
|
2017
Q3 | $1.59M | Sell |
16,685
-392
| -2% | -$29.8K | 0.27% | 69 |
|
|
2017
Q2 | $1.19M | Buy |
17,077
+264
| +2% | +$17.7K | 0.23% | 88 |
|
|
2017
Q1 | $1.12M | Buy |
16,813
+2,220
| +15% | +$140K | 0.22% | 88 |
|
|
2016
Q4 | $914K | Buy |
+14,593
| New | +$891K | 0.21% | 83 |
|
Other funds holding ABBV
VCM
VPM
Parallel Advisors's ABBV Position: Q1 2026 in Review
Parallel Advisors increased its AbbVie (ABBV) stake by 1.3% in Q1 2026, buying an estimated $286K and bringing the position to 103,875 shares worth $22.6M. The position accounts for 0.41% of the portfolio, ranked #45.
Parallel Advisors first reported a position in ABBV in Q4 2016 and has held it in 38 quarters since. The position peaked at $24.4M in Q3 2025. 4,080 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.
- Parallel Advisors held 103,875 shares of AbbVie worth $22.6M as of Q1 2026.
- Parallel Advisors bought 1,290 AbbVie shares in Q1 2026, an estimated $286K.
- AbbVie made up 0.41% of Parallel Advisors's portfolio in Q1 2026, its #45 holding.
- Parallel Advisors first reported a position in AbbVie in Q4 2016 and has held it in 38 quarters since.
- Parallel Advisors's AbbVie position peaked at $24.4M in Q3 2025.
- 4,080 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.
Based on Parallel Advisors's 13F filing for Q1 2026, filed 7 May 2026.